CARLSBAD, Calif.--(BUSINESS WIRE)--Encore Therapeutics, Inc. (ETI) today reported finalizing its proprietary phospholipid nanoemulsion formulation of progesterone (ETI-411). Existing progesterone formulations for Traumatic Brain Injury (TBI) are not suitable for commercial development because they are imprecisely formulated at the bedside, resulting in potential variations in drug dosing and the failure to meet strict release specifications required by regulatory authorities. In addition these formulations lack intellectual property protection and contain components that are not suitable for long-term infusion.
